Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc.

Stock Information for Elutia Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Elutia Inc.

Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch
Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results
Elutia Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41x Launch in $1.5 Billion Plastic and Reconstructive Surgery Market
Elutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026
Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch
Elutia to Present at Planet MicroCap Showcase 2026 on June 17th
A Reno Biotech Just Rang the Nasdaq Bell - Here's Why the Whole Regenerative-Medicine Tape Is Worth Watching
Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.